Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trial. [electronic resource]
Producer: 20160802Description: 30306-16 p. digitalISSN:- 1949-2553
- Annexin A1 -- genetics
- Biomarkers, Tumor -- analysis
- Breast Neoplasms -- chemistry
- Chemotherapy, Adjuvant
- Databases, Genetic
- Disease Progression
- Disease-Free Survival
- Drug Resistance, Neoplasm -- genetics
- Female
- Finland
- Gene Expression Profiling -- methods
- Gene Expression Regulation, Neoplastic
- Genetic Predisposition to Disease
- Humans
- Kaplan-Meier Estimate
- Multivariate Analysis
- Patient Selection
- Phenotype
- Predictive Value of Tests
- Proportional Hazards Models
- Prospective Studies
- Protein Array Analysis
- Protein Kinase Inhibitors -- therapeutic use
- Proteomics -- methods
- Receptor, ErbB-2 -- analysis
- Reproducibility of Results
- Risk Factors
- Time Factors
- Trastuzumab -- therapeutic use
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.